Herrington Grant J, Peterson Joshua J, Cheng Linhai, Allington Benjamin M, Jensen Renato D, Healy Heather S, Correia Marcelo L G
Internal Medicine Residency Program Baylor University Medical Center Dallas Texas USA.
College of Liberal Arts and Sciences University of Iowa Iowa City Iowa USA.
Obes Sci Pract. 2022 Jan 22;8(4):510-524. doi: 10.1002/osp4.589. eCollection 2022 Aug.
This scoping review synthesizes the existing research on the use of very low-calorie diets (VLCDs) in subjects with nonalcoholic fatty liver disease (NAFLD) and end-stage liver disease (ESLD). 19 studies were included, of which 5 were clinical trials, 11 were cohort studies, 1 was a case-control study, and 2 were case series totaling 968 subjects. About 17 studies were focused on patients with NAFLD while the two case series described in patients with ESLD on the transplant list or post-liver transplant. Six studies included subjects managed with VLCDs prior bariatric surgery. Most studies were short term and demonstrated acute improvement of diverse liver biomarkers including liver function tests, indices of hepatosteatosis and reduction in liver size. Adherence rates in these studies were between 69% and 93%. Eight studies did not report any adverse events and four subjects were reported to have discontinued VLCD due to adverse effects in two different studies. Aggregated adverse events were mild. Treatments based on VLCD in subjects with NAFLD seem to be safe and tolerable but can result in mild adverse effects. The findings of this scoping review suggest that the use of VLCD in patients with obesity complicated with NAFLD and potentially in ESLD appear to be effective to induce weight loss and to acutely reduce hepatosteatosis.
本综述综合了关于极低热量饮食(VLCD)在非酒精性脂肪性肝病(NAFLD)和终末期肝病(ESLD)患者中应用的现有研究。纳入了19项研究,其中5项为临床试验,11项为队列研究,1项为病例对照研究,2项为病例系列研究,共计968名受试者。约17项研究聚焦于NAFLD患者,而两项病例系列研究描述的是等待肝移植或肝移植后的ESLD患者。6项研究纳入了在减肥手术前接受VLCD治疗的受试者。大多数研究为短期研究,显示出包括肝功能检查、肝脂肪变性指标和肝脏大小缩小在内的多种肝脏生物标志物的急性改善。这些研究中的依从率在69%至93%之间。8项研究未报告任何不良事件,在两项不同研究中有4名受试者因不良反应而停用VLCD。汇总的不良事件较轻。在NAFLD患者中基于VLCD的治疗似乎是安全且可耐受的,但可能会导致轻微不良反应。本综述的结果表明,在肥胖合并NAFLD以及可能在ESLD患者中使用VLCD似乎对诱导体重减轻和急性减少肝脂肪变性有效。